Loading clinical trials...
Loading clinical trials...
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Conditions
Interventions
PEG-interferon alfa-2b
Locations
32
United States
UAB Comprehensive Cancer Center
Birmingham, Alabama, United States
Lakeland Regional Cancer Center at Lakeland Regional Medical Center
Lakeland, Florida, United States
St. Joseph Medical Center
Bloomington, Illinois, United States
Graham Hospital
Canton, Illinois, United States
Memorial Hospital
Carthage, Illinois, United States
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, United States
Start Date
January 13, 2004
Primary Completion Date
August 1, 2012
Completion Date
June 1, 2014
Last Updated
June 29, 2023
NCT06956690
NCT05649683
NCT00003641
NCT03543969
NCT04079166
NCT05492682
Lead Sponsor
Eastern Cooperative Oncology Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions